227 related articles for article (PubMed ID: 35086793)
1. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
SLAS Discov; 2022 Mar; 27(2):86-94. PubMed ID: 35086793
[TBL] [Abstract][Full Text] [Related]
2. A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry.
Xu M; Pradhan M; Gorshkov K; Petersen JD; Shen M; Guo H; Zhu W; Klumpp-Thomas C; Michael S; Itkin M; Itkin Z; Straus MR; Zimmerberg J; Zheng W; Whittaker GR; Chen CZ
bioRxiv; 2021 Oct; ():. PubMed ID: 34642691
[TBL] [Abstract][Full Text] [Related]
3. Screening of Natural Products Inhibitors of SARS-CoV-2 Entry.
González-Maldonado P; Alvarenga N; Burgos-Edwards A; Flores-Giubi ME; Barúa JE; Romero-Rodríguez MC; Soto-Rifo R; Valiente-Echeverría F; Langjahr P; Cantero-González G; Sotelo PH
Molecules; 2022 Mar; 27(5):. PubMed ID: 35268843
[TBL] [Abstract][Full Text] [Related]
4. Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives.
Tandon R; Sharp JS; Zhang F; Pomin VH; Ashpole NM; Mitra D; McCandless MG; Jin W; Liu H; Sharma P; Linhardt RJ
J Virol; 2021 Jan; 95(3):. PubMed ID: 33173010
[TBL] [Abstract][Full Text] [Related]
5. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
6. The use of Pseudotyped Coronaviruses for the Screening of Entry Inhibitors: Green Tea Extract Inhibits the Entry of SARS-CoV-1, MERSCoV, and SARS-CoV-2 by Blocking Receptor-spike Interaction.
Joseph J; Karthika T; Das VRA; Raj VS
Curr Pharm Biotechnol; 2022; 23(8):1118-1129. PubMed ID: 34375189
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.
Sun H; Wang Y; Chen CZ; Xu M; Guo H; Itkin M; Zheng W; Shen M
Bioorg Med Chem; 2021 May; 38():116119. PubMed ID: 33831697
[TBL] [Abstract][Full Text] [Related]
8. Identification of SARS-CoV-2 entry inhibitors among already approved drugs.
Yang L; Pei RJ; Li H; Ma XN; Zhou Y; Zhu FH; He PL; Tang W; Zhang YC; Xiong J; Xiao SQ; Tong XK; Zhang B; Zuo JP
Acta Pharmacol Sin; 2021 Aug; 42(8):1347-1353. PubMed ID: 33116249
[TBL] [Abstract][Full Text] [Related]
9. Development and utility of a SARS-CoV-2 pseudovirus assay for compound screening and antibody neutralization assays.
Manu AA; Owusu IA; Oyawoye FO; Languon S; Barikisu IA; Tawiah-Eshun S; Quaye O; Donkor KJ; Paemka L; Amegatcher GA; Denyoh PMD; Oduro-Mensah D; Awandare GA; Quashie PK
Heliyon; 2024 May; 10(10):e31392. PubMed ID: 38826759
[TBL] [Abstract][Full Text] [Related]
10. Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19.
Cao J; Liu Y; Zhou M; Dong S; Hou Y; Jia X; Lan X; Zhang Y; Guo J; Xiao G; Wang W
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215943
[TBL] [Abstract][Full Text] [Related]
11. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
12. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.
Shuster A; Pechalrieu D; Jackson CB; Abegg D; Choe H; Adibekian A
ACS Chem Biol; 2021 Dec; 16(12):2845-2851. PubMed ID: 34792325
[TBL] [Abstract][Full Text] [Related]
13. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
Rothan HA; Teoh TC
Mol Biotechnol; 2021 Mar; 63(3):240-248. PubMed ID: 33464543
[TBL] [Abstract][Full Text] [Related]
14. Identification of a broad-spectrum antiviral small molecule against severe acute respiratory syndrome coronavirus and Ebola, Hendra, and Nipah viruses by using a novel high-throughput screening assay.
Elshabrawy HA; Fan J; Haddad CS; Ratia K; Broder CC; Caffrey M; Prabhakar BS
J Virol; 2014 Apr; 88(8):4353-65. PubMed ID: 24501399
[TBL] [Abstract][Full Text] [Related]
15. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay.
Zhou Y; Agudelo J; Lu K; Goetz DH; Hansell E; Chen YT; Roush WR; McKerrow J; Craik CS; Amberg SM; Simmons G
Antiviral Res; 2011 Nov; 92(2):187-94. PubMed ID: 21820471
[TBL] [Abstract][Full Text] [Related]
17. A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon.
Li N; Chen XL; Li Q; Zhang ZR; Deng CL; Zhang B; Li XD; Ye HQ
Emerg Microbes Infect; 2022 Dec; 11(1):465-476. PubMed ID: 35034586
[TBL] [Abstract][Full Text] [Related]
18. Direct inhibitory effect on viral entry of influenza A and SARS-CoV-2 viruses by azithromycin.
Du X; Zuo X; Meng F; Han C; Ouyang W; Han Y; Gu Y; Zhao X; Xu F; Qin FX
Cell Prolif; 2021 Jan; 54(1):e12953. PubMed ID: 33211371
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
